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Introduction
Esophageal cancer is the eighth most commonly diagnosed
cancer worldwide with approximately 456,000 patients per
year [1]. In the western world, the incidence of esophageal can-
cer is rising and it is the sixth most common cause of cancer-
related death with a 5-year survival of less than 20% [1]. In less
than two-thirds of cases, patients are not eligible for surgery
with curative intent. Thus, palliation is the main aim in manage-
ment. Palliative treatment consists of chemotherapy, radio-
therapy or combined chemoradiotherapy, as well as local surgi-
cal treatments such as dilatation and stenting, in addition to
supportive care [2]. Different response rates and subsequent
treatments with a high prevalence of reported side effects (fa-
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ABSTRACT
Background and study aims Esophageal cancer is on the
rise in the western world and the disease has a poor 5-year
survival prognosis below 20%. Electrochemotherapy is a
treatment where a chemotherapeutic drug is combined
with locally applied electrical pulses, in order to increase
the drug’s cytotoxicity in malignant cells. This study pre-
sents the first results with electrochemotherapy treatment
in esophageal cancer.
Patients and methods In this first-in-human trial, six pa-
tients with advanced esophageal cancer were treated with
electrochemotherapy using intravenous bleomycin. All
side effects and adverse events (AEs) were registered and
the patients were later evaluated with gastroscopy and
18F-fluorodeoxyglucose positron emission tomography/
magnetic resonance imaging (18F-FDG PET/MRI).
Results Treatment were well tolerated, main AEs being
nausea, vomiting, oral thrush, pneumonia, retrosternal
pain, fever, and hoarseness. No serious complications were
observed. Five patients had a visual tumor response con-
firmed by gastroscopy. In two cases, these findings were
confirmed with 18F-FDG PET/MRI as it revealed a reduction
of total tumor mass.
Conclusion Electrochemotherapy in patients with ad-
vanced esophageal cancer was conducted without major
safety concerns. This study paves the way for larger studies,
which may further elucidate response rates for and side ef-
fects of this new treatment.
Original article
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tigue, vomiting, nausea, paresthesia, cardiac toxicity, kidney
toxicity, and retrosternal pain) are, however, the common sce-
nario [3]. Hence, new treatment options are warranted.
Electrochemotherapy combines electroporation with che-
motherapy; reversible electroporation facilitates transport of
molecules across the cell membrane. Short high-voltage pulses
are applied to the malignant cells, which destabilize the mem-
brane and create temporary pores [4]. Through these passages,
large molecules (i. e. various types of cytostatic agents) that
normally are impermeable to the cell membrane are able to
cross into the cytosol [5]. Previous studies have proven bleomy-
cin to be an efficient chemotherapeutic drug in combination
with electroporation as it increases its cytotoxic ability more
than 300-fold [6, 7]. The first clinical trial testing electrochemo-
therapy was reported in 1991 [8] and since then, several studies
have investigated it in different cancer types [9–16]. To date,
no human clinical studies regarding patients with esophageal
cancer treated by electrochemotherapy have been reported.
The primary endpoint of this study was to evaluate the safe-
ty and feasibility of a novel endoscopic approach for electro-
chemotherapy in patients with an advanced esophageal cancer.
Patients and methods
Study design
This was a phase I, investigator-initiated, prospective, observa-
tional, non-comparative trial of electrochemotherapy in esoph-
ageal cancer. The primary endpoint was assessment of safety,
and secondary endpoints were assessment of response meas-
ured by 18F-fluorodeoxyglucose positron emission tomog-
raphy/magnetic resonance imaging (18F-FDG PET/MRI), gas-
troscopies, pain score (visual analog scale), dysphagia score
(Mellow and Pink dysphagia score [17]), and quality of life ques-
tionnaires (European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire (EORTCQLQ-C30)).
Patients
The protocol allowed for inclusion of eight patients. Since the
primary endpoint was safety in this phase I first-in-man trial,
the subject number was low. Only patients ineligible for poten-
tially curative intended surgery were candidates. Inclusion
criteria were: age≥18 years, histologically verified malignant
esophageal tumor (adenocarcinoma or squamous cell cancer),
expected survival time≥3 months, WHO performance status
≤2 [18], platelets≥50 billion/L, International Normalized Ratio
< 1.5 (medical correction was allowed), and s-creatinine
<150µmol/L. Moreover, patients had to have locally progressive
disease despite previous treatment with chemoradiotherapy or
locally progressive disease despite previous treatment with pal-
liative radiotherapy and not be candidates for systemic chemo-
therapy. Written informed consent was required. Exclusion
criteria were: non-correctable coagulation disorders, clinically
significant cardiac arrhythmias, pregnancy or lactation/breast-
feeding, concurrent treatment with another investigational
medicinal product, contraindications for use of bleomycin
(acute pulmonary infection, severe pulmonary disease, pre-
viously allergic reactions to bleomycin, or a previously regimen
of bleomycin with a cumulative dose >240.000UI/m2) or con-
traindications to 18F-FDG PET/MRI. Moreover, patients with
any other clinical condition or prior therapy which, in the opi-
nion of the investigator, would make them unsuitable for the
study or unable to comply with the study requirements were
not included. Women of childbearing potential and sexually ac-
tive men had to use adequate contraception during the trial.
Procedure
Prior to the procedure, all patients had a full physical examina-
tion, blood biochemistry, a chest x-ray or chest computed to-
mography and an electrocardiogram. In addition, a baseline
gastroscopy including biopsies and an 18F-FDG PET/MRI were
done.
The treatment was performed under general anesthesia. Pa-
tients were anesthetized with propofol and remifentanil and
endotracheal intubation was performed. To prevent cardiac ar-
rhythmias, three electrodes were placed on the chest and con-
nected to an AccuSync ECG triggering monitor (AccuSync 42
ECG triggering device, AccuSync Medical Research Corporation,
Milford, Connecticut, United States). To minimize risk of lung
toxicity from bleomycin, the fraction of inspired oxygen was
limited to a maximum of 30% during anesthesia, according to
ESOPE (European Standard Operating Procedure on Electroche-
motherapy) [5]. Furthermore, patients were relaxed during the
treatment to prevent muscle contractions.
▶ Fig. 1 EndoVE (source: Cork Cancer Research Centre). Images of
the device used in the trial- EndoVE®. The electrode is attached to
an endoscope. Tumor tissue is captured in place within the cham-
ber (1 ×1×1.5 cm) of the device by a vacuum; this brings the tu-
mor in contact with the two parallel electrodes which deliver pul-
ses in 100µs intervals. The procedure is repeated until the whole
tumor area is covered.
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Bleomycin was administrated intravenously as 15,000 units/
m2 in a fast infusion diluted in 250mL sodium chloride. Eight
minutes after administration, the treatment began according
to ESOPE [5]. The endoscopic electrode, EndoVE (Mirai Medical,
Ireland) was attached to a scope (▶Fig.1) and connected to a
square wave pulse generator (Cliniporator, IGEA, Capri, Italy).
The Cliniporator was further connected to a surgical suction
pump (0–760mmHg) and the ECG triggering monitor. The
Cliniporator delivered sequences consisting of eight pulses at
100 µs duration with a frequency of 5 kHz and amplitude of
760 V/cm. After the electrode was placed on the tumor tissue,
a vacuum was applied and the pulse sequences were delivered.
This was repeated until the entire tumor area was covered. A
nasal feeding tube was inserted and left in place for 7 days after
treatment to ensure sufficient nutrition intake in case of local
edema or post-treatment pain. Patients were discharged the
same afternoon as the procedure or the day after.
Image acquisition
Baseline and follow-up 18F-FDG PET/MRI were performed on a
3 Tesla Biograph mMR (Siemens Medical Solutions). PET were
acquired from mid-thoracic to upper gastrointestinal level ac-
quired 60 minutes after administration of 18F-FDG with a dose
of 4MBq/kg preceded by at least 6 hours of fasting (one bed 6-
minute acquisition using 3D OP-OSEM image reconstruction
with 4 iterations, 21 subsets using a 344x344 matrix and a
4.0 mm Gaussian post-filter and Siemens standard four-com-
partment-attenuation map). Before the scanning, patients
were given 20mg of hyoscinbutylbromid to reduce intestinal
motility. The following MR sequences were acquired: T2-
weighted Half Fourier Acquisition Single Shot Turbo Spin Echo
(HASTE) [TR 1500ms, TE 117ms, voxel size 1.5 ×1.2mm2, and
21 slices of 5.5mm thickness] in sagittal, transversal and coro-
nal orientation. Transversal HASTE and all following imaging
were centered on the left part of the diaphragm. Imaging fur-
ther comprised sagittal-oriented T1-weighted imaging [TR
4.25ms, TE 1.88ms, voxel size 1.7×1.3mm2, 52 slices of 4mm
thickness], transversal orientated HASTE [TR 1800ms, TE
95ms, voxel size 1.7 ×1.2mm2, and 35 slices of 5.0mm thick-
ness] and two echo planar Diffusion Weighted Imaging (DWI)
[10300ms, TE 73ms, voxel size 3.7×3.0mm2, and 34 slices of
5.0mm thickness] in transversal orientation with b-values of 0,
50, 400, and 800 s/mm2. T1 and T2 weighted imaging was per-
formed in breath-hold, whereas DWI was respiratory triggered
using a MR navigator placed on the diaphragm.
Follow-up
Seven days after treatment, all patients had a physical examina-
tion and patient-reported measures such as quality of life, dys-
phagia, and retrosternal pain score were recorded. This was re-
peated after 4 and 8 weeks. Safety was assessed by registering
adverse events (AEs) and adverse device events (ADEs). An AE
was defined as an event occurring during treatment or within
14 days after that was not present before. Severe adverse
events (SAEs) were recorded according to Good Clinical Prac-
tice (GCP) provided by International Council for Harmonization
of Technical Requirements for Pharmaceuticals for Human Use
[19].
Response was evaluated via a gastroscopy and an 18F-FDG
PET/MRI at 4 and 8 weeks post-treatment. All gastroscopies
were performed by a senior surgeon from the upper gastroin-
testinal team. The imaging response evaluation was performed
by the same radiologists and nuclear physician working side by
side. PET response was evaluated visually and by measuring
maximum standardized uptake value (SUVmax) of the tumor
and the treated region and >30% decrease from baseline con-
sidered significant changes. MR anatomical imaging and diffu-
sion-weighted imaging was assessed for visible tumor tissue,
occurrence of metastatic disease, local lymph node involve-
ment, treatment effects (edema of esophageal wall, formation
of fibrous scar tissue) and treatment side effects. RECIST 1.1
criteria were not applied, as the treatment method is compar-
able to debulking surgery rather than systemic therapy.
Based on experience from the first patients, midway through
the trial, supportive drugs were introduced to palliate side ef-
fects; prednisolone 50mg daily for 14 days followed by 25mg
daily for 7 days, fluconazole 100mg daily for 2 weeks and on-
dansetron 8mg twice daily for 14 days.
Ethics
The intention of treatment was palliative and all included pa-
tients had already been offered palliative standard care without
favorable response or were considered unsuitable for standard
care. The protocol was approved by the Danish Medicines
Agency, the Regional Ethics Committee (H-16016381) and the
Danish Data Protection Agency. EudraCT nr. 2015-005246-59.
The trial was monitored by the Good Clinical Practice unit at Co-
penhagen University Hospital, Bispebjerg Hospital, Denmark.
Statistics
This was a small exploratory trial, so only descriptive statistics
were used.
Results
Patient characteristics
Six men and one woman, aged 59 to 88 years, with a perform-
ance status 1–2, and different comorbidities were included in
the study (▶Table1). Six patients were treated whereas the
first included patient could not participate due to a stent that
could not be removed before the electrochemotherapy (ECT)
procedure. The patients were treated between September
2016 and February 2017. Six patients had received oncological
treatment for their esophageal cancer before enrollment. Four
patients had loco-regional disease and three patients had me-
tastatic disease. All seven patients used analgesics daily, and
all but one could only take semifluid food or liquids when re-
ferred.
Egeland Charlotte et al. Endoscopic electrochemotherapy for… Endoscopy International Open 2018; 06: E727–E734 E729
Treatment session
Between nine and 48 electrical pulse sequences were delivered
during the treatment sessions, depending on tumor size and
cranial-caudal length. Treatment duration varied from 24 to 59
minutes (▶Table 2). In three of the six treated patients, only
the oral part of the tumor could be treated due to stricturing
of the tumor that could not be passed by the electrode on the
scope.
▶ Table 1 Patients characteristics.
Patient
no.
Sex
Age
Primary
diagno-
sis
TNM at diag-
nosis and
histology
Comorbidity PS1 Localization in
esophagus (from
incisor teeth)
Previous oncological/
surgical treatment
1 Male
77 yr
Jun
2016
T3N1M0
SCC
COPD 2 32–40 cm Stent
RT: 3Gy×10 F (esophagus)
2 Male
59 yr
May
2015
T4bN0M0
ADC
Liver insufficiency (Child
Pugh A), esophageal vari-
ces
1 20–34 cm Capecitabine/oxaliplatin/
trastuzumab
RCT: 2Gy×25 F +Cisplatin/
5– fluorouracil
Docetaxel
3 Male
60 yr
Apr
2015
T3N2M1
ADC
DMII
(Liver and osteolytic
metastases)
2 34–41 cm
(“metastatic
islands” starting
from 20 cm)
Capecitabine/ trastuzumab
RT: 3Gy×10 F (esophagus)
RT: 5Gy×5 F (costae)
4 Male
84 yr
Feb
2016
T2 /3N0M0
ADC
Hypertension, AF, epilepsy
Previous: prostate cancer
2 34–42 cm RT: 3Gy×10 F (esophagus)
5 Male
80 yr
Apr
2014
T1N1M0
ADC
Hypertension, AF, hy-
percholesterolemia,
essential thrombocytosis
Previous: ischemic stroke
2 34–42 cm RT: 3Gy×10 F (esophagus)
6 Fe-
male
72 yr
Nov
2015
TxNxM1
ADC
Hypertension, DMII
(Peritoneal carcinonoma-
tosis)
1 38–40 cm 3Gy×10 F (esophagus)
Argon plasma coagulation
Capecitabine/oxaliplatin/
trastuzumab
Irinotecan
7 Male
88 yr
Feb
2017
T3N0M0
ADC
Parkinson’s disease, AA,
possible prostate cancer
2 30–40 cm None
COPD, chronic obstructive pulmonary disease; RT, radiotherapy; Gy, Gray; F, fraction; RCT, radiochemotherapy; SCC, squamous cell carcinoma; ADC, adenocarcino-
ma; DMII, diabetes mellitus type II; AF, atrial fibrillation; AA, aortic aneurysm
1 Performance status according to WHO/ECOG [18]
▶ Table 2 Procedure.
Patient
no.
Bleomycin
(IU)
Pulse sequences of
each 8 pulses (n)
Voltage applied
(V)
Treatment duration
(min)
Comment
2 25,500 9 960 59 Due to stenosis only the oral 5 cm of the
tumor was treated.
3 28,350 32 960 37 The entire tumor area was treated.
4 30,450 48 960 37 The entire tumor was treated.
5 25,650 25 960 33 Due to stenosis, the caudal part of the
tumor was not treated.
6 29,100 16 960 31 The entire tumor area was treated.
7 27,900 30 960 24 Due to stenosis, the caudal 2 cm of the
tumor was not treated.
Describes the procedure specific details, including dosage of bleomycin, pulses delivered, voltage, treatment duration, and comments. Patient number 1 was not
treated.
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Safety
All AEs and ADEs occurring within 14 days post-treatment were
recorded (▶Table 3). No serious complications (perforation,
perioperative bleeding or cardiac arrhythmias) related to the
treatment session were recorded. No ADEs or device malfunc-
tions concerning safety were reported. Among the first three
patients, fever within 12 hours after treatment, hoarseness,
coughing up necrotic tissue, oral thrush, pneumonia, dehydra-
tion, vomiting, nausea, retrosternal pain, and weight loss were
reported. After supportive drugs (prednisolone, ondansetron
and fluconazole) were introduced, incidence of AEs was re-
duced. Three patients had AEs leading to hospitalization after
treatment. Duration of hospitalization length was from 1 to 3
days. Patient Number 2 died 3 months after the study treat-
ment following a shorter hospitalization, most likely due to
newly developed lung metastasis and pneumonia. The third pa-
tient died 2 months after the given treatment, although he suf-
fered from both liver and osteolytic metastasis on enrollment.
Supportive treatment
All though electrochemotherapy is well described for cuta-
neous tumors, this was the first study in esophageal cancer
and special considerations may be necessary for this indication.
Because the first treated patients in the study reported nausea,
vomiting, oral thrush and problems swallowing, it was decided
to prophylactically administer ondansetron (8mg twice daily
for 14 days), prednisolone (50mg daily for 14 days followed by
25mg daily for 7 days), and prophylaxis for fungal infections
(fluconazole 100mg daily for 14 days). The patients receiving
this supportive treatment experienced fewer side effects (▶Ta-
ble 3).
▶ Table 3 Adverse events.
Patient no. Adverse events/reactions CTCAE-grading Serious adverse events/reactions Survival
2 Fever/chills (< 12h) 2 Prolonged hospitalization within 24h post-
treatment (fever).
Hospitalization after coughing up necrotic
tissue, no intervention.
3 months
Hoarseness 1
Oral thrush 1
Pneumonia 2
Coughing up necrotic tissue 1
Dysphagia 1
Mucus 1
3 Fever/chills ( < 12h) 1 Prolonged hospitalization within 24h post-
treatment (fever).
Hospitalization due to nausea and dehydra-
tion.
2 months
Hoarseness 1
Oral trush 1
Dehydration 2
Nausea/vomiting 2
Retrosternal pain 2
Weight loss 1
4 Retrosternal pain 2 Hospitalization due to food intake related
pain.
Alive at 9 months
Oral thrush 1
5 Dysphagia 1 None Alive at 7 months
Weight loss 1
6 Nausea/vomiting 1 None Alive at 6 months
Retrosternal pain 1
Weight loss 1
Oral thrush 1
7 None – Prolonged hospitalization1 within 48h post
treatment, due to problems placing feeding
tube.
4 months
All adverse events occurring during the registration period, 14 days post procedural. Moreover, the serious adverse events are listed, as well as survival.
CTCAE grading: 1 =mild, 2=moderate, 3 = severe, 4 = life-threatening, 5=death related to AE [20].
1 Was not considered as an actual serious adverse event as it was not related to the given treatment but was still reported to the Danish Medical Agency.
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▶ Fig. 3 Imaging treatment response. 18F-FDG PET/MRI from patient number 5. From left to right: MRI; 18F-FDG PET; 18F-FDG PET/MRI;
MIP*-PET. The arrows show the tumor area; the circle shows the treated area at 8 weeks. Due to stenosis, the distal part could not be treated.
In the treated area there is no sign of residual tumor and treatment sequelae is seen as fibrosis. There is no significant change in 18F-FDG
activity (SUVmax at baseline 7,59, SUVmax at 8 weeks 7,06). *Maximun intensity projection
Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
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▶ Fig. 2 Endoscopic treatment response. Individual endoscopic treatment response. The image at the top shows the tumor before treatment,
the images in the middle show the tumors after four weeks and the lowest line shows the tumor after eight weeks. Earlier ulcerated tissue is
replaced with necrotic tissue with a fibrin layer and the tumors are found less exophytic. Not all patients had the 8 week endoscopy performed,
where data are not available frames are left dark.
E732 Egeland Charlotte et al. Endoscopic electrochemotherapy for… Endoscopy International Open 2018; 06: E727–E734
Original article
Follow-up and response evaluation
Five of six treated patients were evaluated with gastroscopies
and imaging (the last patient suffered head trauma unrelated
to the treatment and could not be evaluated). Visual tumor re-
sponse was reported from all postoperative gastroscopies. The
esophageal mucosa demonstrating previous ulcerated tumor
tissue was replaced with necrotic tissue covered with a fibrin
layer (▶Fig. 2). In two patients, these findings were confirmed
by PET/MRI with a no longer visible residual tumor in the treat-
ed area (▶Fig. 3). One patient did not respond (evaluated with
chest CT) and in two patients, the amount of residual tumor tis-
sue could not be assessed on MR images. Tumor progression
was not observed in any patient, but progression of regional,
malignant suspicious lymph nodes was observed in one patient.
Treatment sequelae were seen as fibrosis and/or local edema.
Evaluation of PET images showed no significant change of 18F-
FDG-activity in the treated tumor areas on any follow-up ima-
ges compared to baseline (▶Table 4).
Adverse event report
Three patients requested a second treatment, but due to a
stricturing tumor in one case and poor performance status in
the other two cases, a second treatment was considered unsui-
table. On the EORTCQLQ-C30 assessment within the first 8
weeks after treatment, three patients reported impaired quali-
ty of life, one patient reported an increase and one patient re-
ported no change. The last patient was not assessed due to
head trauma. The treatment did not have a pain relief effect in
in any of the cases as evidenced by retrosternal pain score
measured by Visual Analog Scale within the first 8 weeks post-
treatment. Regarding dysphagia, four patients reported that it
increased during the follow-up period (a maximum increment
of one level at the used scale), one patient reported no change
and one patient reported relief of dysphagia (decrement of one
level of the used scale).
Discussion
In this first-in-human phase I study, endoscopic electrochemo-
therapy in patients with advanced esophageal cancer was tech-
nically feasible, without serious treatment-related complica-
tions. Moreover, tumor regression was observed.
No serious complications were reported, no AEs were rated
higher than two based on CTCAE (Common Terminology Crite-
ria for AEs) [20]. Most reported AEs were well-known side ef-
fects of electroporation and bleomycin, and they were further
reduced after introduction of supportive drugs. The reported
side effects should be considered in relation to the patients’
stage of local disease, age and comorbidities. In further studies,
this regimen may be further refined, but at this time, we would
recommend it for the use of electroporation-based treatments
in esophageal cancer. To evaluate efficiency and toxicity of
bleomycin, a retrospective analysis of 57 patients with cuta-
neous tumors has suggested that a reduced dose of bleomycin
(10000 or 13500 IU/m2) could be as efficient as the standard
dose [21]. However, this must be prospectively confirmed be-
fore adoption in a clinical setting.
Tumor regression was visually confirmed endoscopically in
all patients and was further confirmed with MRI in two patients.
In this study, 18-F FDG activity does not seem suitable for eval-
uating treatment response this early in the follow-up period as
there in all cases was unchanged increased activity in the treat-
ed region. Most likely this was due to a local inflammatory re-
sponse, which was still active 8 weeks after treatment, possibly
due to position of the tumor in the esophagus. The results from
gastroscopies and MRI indicate that electrochemotherapy also
induces tumor necrosis in that area. The study was not de-
signed nor powered to show any relationship between gastro-
scopy or MRI finding and survival.
Several studies previously have investigated ECT in cuta-
neous tumors and cutaneous metastases where it is second-
line therapy in many European countries. Mucosal tumors such
as head-and-neck [12–14] and intestinal liver metastases [15]
have also been evaluated with good response. Furthermore,
electrochemotherapy has been illustrated in pancreatic cancer
in a preclinical study [16]. Recently in a phase I study, electro-
chemotherapy was evaluated in colorectal cancer with an
endoscopic electrode similar to the one used in this trial [22].
None of the patients reported pain relief, one patient report-
ed an improvement in quality of life and two patients reported
no change or a relief in dysphagia during the study period. The
study design was not powered to demonstrate the palliative ef-
▶ Table 4 Description of response evaluation (18F-FDG PET/MRI).
Patient no. Imaging description
2 4 weeks:
No sign of residual tumor in the proximal part of
esophagus (treated area). Treatment sequelae in the
treated area, seen as fibrosis. No tumor progression
in non-treated area.
No significant changes in 18F-FDG-activity.
3 4 weeks:
The amount of residual tumor could not be assessed.
No sign of local progression. Treatment sequelae,
seen as edema in the treated area.
No significant changes in 18F-FDG-activity.
4 8 weeks:
No signs of local progression, amount of residual
tumor could not be assessed due to local edema
(treatment sequelae).
No significant changes in 18F-FDG-activity.
5 8 weeks:
In the treated area there was no sign of residual
tumor. In the untreated, distal area there was no sign
of tumor progression. Treatment sequelae, seen as
fibrosis.
No significant changes in 18F-FDG-activity.
6 4 weeks (evaluation from CT1):
No visual changes in the treated area, no local pro-
gression.
Individual 18F-FDG PET/MRI response evaluation. Patient number 7 was lost
to follow-up due to a head trauma.
1 Declined the second PET/MRI.
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fect of the treatment, as it was a safety and feasibly study. In
addition, the majority of patients were diagnosed more than a
year ago and were already suffering from both physical and psy-
chological symptoms as well as existential considerations.
For less obstructive tumors the endoscopic electrode proved
to be manageable, but for more obstructive tumors it was not
possible to pass the stricture with the scope and the attached
electrode. Consequently, impaired visibility could be a practical
challenge. Further development of the electrodes as well as
possibly treating the patients at stages before serious constric-
tion could improve this situation.
Conclusion
In conclusion, this first-in-human study reports electrochemo-
therapy in patients with advanced esophageal cancer as feasi-
ble and safe, although stricturing tumors were challenging to
treat. Tumor regression was reported in all patients from the
gastroscopies and confirmed with MRI in two cases. Larger
studies are warranted to further investigate electrochemother-
apy for esophageal cancer, both with respect to response rate
and more extensive reporting on quality-of-life data.
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